Europeanhhm

Abbott's TriClip™ Granted FDA Approval as Breakthrough Device for Repairing Leaky Tricuspid Heart Valve

Wednesday, April 03, 2024

Abbott has announced that its innovative TriClip™ transcatheter edge-to-edge repair (TEER) system has received approval from the U.S. Food and Drug Administration (FDA). This approval marks a significant development in the treatment of tricuspid regurgitation (TR), a condition characterized by a leaky tricuspid valve that causes blood to flow backward in the heart.

TR can lead to debilitating symptoms such as fatigue and shortness of breath, and if left untreated, it can result in serious health issues including atrial fibrillation, heart failure, and even death. Until now, treatment options for TR have been limited, particularly for patients who are not suitable candidates for open-heart surgery due to age or health complications.

The TriClip system offers a minimally invasive alternative to traditional surgery, allowing physicians to repair the tricuspid valve and restore proper blood flow without subjecting patients to the risks associated with open-heart procedures. The approval of TriClip follows a positive recommendation from the Circulatory System Devices Panel of the Medical Devices Advisory Committee, confirming its safety and effectiveness in treating TR.

With TriClip, patients can experience improved quality of life and reduced hospital stays compared to traditional surgical interventions. The system leverages clip-based technology similar to Abbott's MitraClip™ device, providing a tailored solution for addressing the complex anatomy of the tricuspid valve.

Overall, the approval of TriClip represents a significant advancement in the management of TR, offering new hope for patients and healthcare providers in addressing this challenging heart condition.

Source: prnewswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024